- Home
- ZYME
ZYME
Zymeworks Inc.
as 03-28-2025 4:00pm EST
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | MIDDLETOWN |
| Market Cap: | 983.6M | IPO Year: | 2017 |
| Target Price: | $19.50 | AVG Volume (30 days): | 746.6K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.97 - $17.70 | Next Earning Date: | 03-05-2025 |
| Revenue: | $76,304,000 | Revenue Growth: | 0.38% |
| Revenue Growth (this year): | 19.85% | Revenue Growth (next year): | 100.06% |
Stock Insider Trading Activity of Zymeworks Inc. (ZYME)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | ZYME | Director10% Owner | Mar 11 '25 | Buy | $12.08 | 1,081,980 | $13,120,914.17 | 16,040,851 | |
| EcoR1 Capital, LLC | ZYME | Director10% Owner | Jan 16 '25 | Buy | $13.88 | 141,429 | $1,963,538.26 | 16,040,851 | |
| EcoR1 Capital, LLC | ZYME | Director10% Owner | Jan 13 '25 | Buy | $13.66 | 167,654 | $2,278,811.37 | 16,040,851 | |
| EcoR1 Capital, LLC | ZYME | Director10% Owner | Jan 8 '25 | Buy | $13.60 | 225,119 | $2,974,818.88 | 16,040,851 | |
| Smith Jeffrey T L | ZYME | EVP & Chief Medical Officer | Jan 6 '25 | Sell | $14.92 | 11,110 | $165,806.75 | 8,890 | |
| Moore Paul Andrew | ZYME | Chief Scientific Officer | Jan 6 '25 | Sell | $14.92 | 21,200 | $316,390.92 | 23,333 | |
| Galbraith Kenneth | ZYME | Chair & CEO | Jan 6 '25 | Sell | $14.92 | 57,291 | $855,016.61 | 80,803 | |
| EcoR1 Capital, LLC | ZYME | Director10% Owner | Dec 30 '24 | Buy | $14.61 | 363,369 | $5,321,175.87 | 16,040,851 |
Latest Zymeworks Inc. News
ZYME Breaking Stock News: Dive into ZYME Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Zymeworks Announces Participation in Upcoming Investor Conferences
GlobeNewswire
4 days ago
Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
Simply Wall St.
19 days ago
Analysts Just Shipped A Captivating Upgrade To Their Zymeworks Inc. (NASDAQ:ZYME) Estimates
GlobeNewswire
24 days ago
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
GuruFocus.com
25 days ago
Zymeworks Inc (ZYME) Q4 2024 Earnings Report Preview: What To Look For
GlobeNewswire
a month ago
Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration
GlobeNewswire
a month ago
Zymeworks Announces Participation in Upcoming Investor Conferences
GlobeNewswire
a month ago
Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors
Compare ZYME vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZYME Zymeworks Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.